Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Activatable Multimodal Probes for in Vivo Imaging and Theranostics

Activatable Peptide-Based Nanoprobes for Multimodal Imaging in Vivo

Optical probes and the applications in multimodality imaging.

Recent Development on Peptide-Based Probes for Multifunctional Biomedical Imaging

Activatable Molecular Probes For Cancer Imaging

Nanomaterial-based activatable imaging probes: from design to biological applications

Molecular Imaging of Enzyme Activity in Vivo Using Activatable Probes

Multimodal Molecular Imaging: Current Status and Future Directions

Molecular imaging: design mechanism and bioapplications

Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Research progress of probe labeled-multimodality molecular imaging technologies

Multimodality reporter gene imaging: Construction strategies and application

Recent developments in multimodality fluorescence imaging probes

Activatable fluorescent probes for real-time imaging-guided tumor therapy

Activatable luminescent probes for imaging brain diseases

Progress on Multi-Modality Molecular Imaging

Activatable NIR-II Probe for Tumor Imaging

Multifunctional fluorescent probes "killing two birds with one stone" - recent progress and outlook

Recent Advances in Activatable Probes for Molecular Imaging by Stimuli-Controlled Disassembly

Recent Advances on Activatable NIR‐II Fluorescence Probes for Biomedical Imaging